Oncotarget.net features press releases on the latest oncology research, as well as interviews from the distinguished network of authors who continue to publish their research with Oncotarget.

Category: Oncotarget

Figure 2: Rapamycin prevents cancer by slowing tumor progression (hypothetical schema).

Oncotarget

Cancer Prevention With Rapamycin

April 17, 2023

“[...] long-term treatment with rapamycin slows down aging, a major risk factor for cancer [...]” Listen to an audio version of this press release BUFFALO, NY- April 17, 2023 –… read more

Figure 1: Pre- and post-treatment scans confirmed partial responder. (From a phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.”)

Oncotarget

Riluzole and Sorafenib in Patients With Advanced Solid Tumors: A Phase I Trial

April 12, 2023

“Our phase I study determined the tolerable dose of this combination and investigated its biologic effects.” Listen to an audio version of this press release BUFFALO, NY- April 12, 2023… read more

Figure 2: Active pharmacological intervention trials in TNBC.

Oncotarget

Crosstalk Between Triple Negative Breast Cancer and Microenvironment

April 10, 2023

“[...] the study of immunotherapy for treating triple negative breast cancer might still be at its early stages of development but is full of future promise.” Listen to an audio… read more

Oncotarget

Cancer-Associated Fibroblasts: Challenges and Opportunities

April 5, 2023

“Beyond detection of cancer, CAFs are being actively pursued as targets for therapy.” Listen to an audio version of this press release BUFFALO, NY- April 5, 2023 – A new… read more

Figure 1: The molecular mechanism(s) of how Wnt5a signaling could (i) induce ROR1 and cortactin association, tyrosine phosphorylation of cortactin, and activation of RhoA, (ii) enhance F-actin polymerization, and (iii) subsequently promote migration or metastasis of cancer cells.

Oncotarget

Impact of Cortactin in Cancer Progression

April 4, 2023

“Cortactin (also known as EMS1 or CTTN) is expressed broadly in a variety of cancers [...]” Listen to an audio version of this press release BUFFALO, NY- April 4, 2023… read more

Oncotarget

Oncotarget at AACR Annual Meeting 2023

April 4, 2023

Impact Journals (Oncotarget's publisher) is proud to participate at the American Association for Cancer Research (AACR) Annual Meeting 2023, which convenes April 14-19 in Orlando, Florida. Listen to an audio version of… read more

Figure 7: Effects of TGF-β receptor inhibitor EW7197 with and without TGF-β1 for LSR, TRIC, OCLN, and CLDN-2 in human lung epithelial cells (HLE) cells with and without 10% FBS.

Oncotarget

Downregulation of Angulin-1/LSR Induces Malignancy in Lung Adenocarcinoma

March 29, 2023

“In the present study, we found that downregulation of angulin-1/LSR induced malignancy via upregulation of EGF-dependent CLDN-2 and TGF-β-dependent cell metabolism in human lung adenocarcinoma.” Listen to an audio version… read more

Figure 5: NSL-YHJ-2-27 suppresses cancer cell migration and invasion.

Oncotarget

Oncotarget | Polyisoprenylated Cysteinyl Amide Inhibitors Deplete G-Proteins in Cancer Cells

March 28, 2023

“[...] mutations in G-proteins have been associated in the progress of several cancers [...]” Listen to an audio version of this press release BUFFALO, NY- March 28, 2023 – A… read more

Figure 6: Overexpression of GPC1 increases proliferation of T24 cells.

Oncotarget

Oncotarget | Attenuation of Cancer Proliferation by Suppression of Glypican-1

March 22, 2023

“This study was designed to increase the knowledge on the potential of GPCs and in particular GPC1 as a biomarker in cancer diagnosis and prognosis.” Listen to an audio version… read more

Oncotarget

Oncotarget | Unlocking the Potential of Molecular-Driven Stratification of Osteosarcoma

March 20, 2023

“We are very enthusiastic about these initiatives and the recent rate of discoveries in OSA, and hopeful that they will bring actionable targets for OSA.” Listen to an audio version… read more